Non-Drug Interventions (Q3679762): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: translated_label) |
(Changed an Item: Edited by the beneficiary bot - attach the beneficiary based on the string) |
||
| Property / beneficiary | |||
| Property / beneficiary: Q3764747 / rank | |||
Normal rank | |||
Revision as of 16:33, 24 November 2021
Project Q3679762 in France
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Non-Drug Interventions |
Project Q3679762 in France |
Statements
27,016.0 Euro
0 references
180,850.0 Euro
0 references
14.94 percent
0 references
1 April 2015
0 references
31 May 2017
0 references
SATT AxLR
0 references
Les interventions non médicamenteuses (INM) regroupent trois catégories distinctes que sont les thérapies physiques, les thérapies psychologiques et la nutrition. Ces interventions visent à améliorer la qualité de vie d'un patient, sans pour autant se substituer aux thérapies classiques et conventionnelles. Elles s'adressent principalement aux personnes âgées et patients atteintes de maladies chroniques. Depuis 2010 les INM connaissent un essor considérable de la part des acteurs industriels, mais elles nécessitent encore la preuve de leur efficacité en termes de rapport coût / bénéfices. La plate-forme CEPS, créée au sein du laboratoire EPSYLON de Montpellier effectue ainsi des recherches sur des méthodes d'analyse de ce rapport coûts / avantages, en vue de les appliquer aux produits et services INM développés par les acteurs industriels. (French)
0 references
Non-drug interventions (NMIs) fall into three distinct categories: physical therapies, psychological therapies, and nutrition. These interventions aim to improve a patient’s quality of life, without replacing conventional and conventional therapies. They are aimed primarily at elderly people and patients with chronic diseases. Since 2010 NMIs have experienced considerable growth on the part of industrial players, but they still require proof of their cost-benefit effectiveness. The CEPS platform, created within the EPSYLON laboratory in Montpellier, thus carries out research on methods for analysing this cost-benefit ratio, with a view to applying them to INM products and services developed by industrial actors. (English)
18 November 2021
0 references
Identifiers
LR0008866
0 references